Altimmune, Inc.ALTEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ALT Q3 2025 Key Financial Metrics
Revenue
$5.0K
Gross Profit
N/A
Operating Profit
$-20.9M
Net Profit
$-19.0M
Gross Margin
N/A
Operating Margin
-417180.0%
Net Margin
-380280.0%
YoY Growth
0.0%
EPS
$-0.21
Financial Flow
Altimmune, Inc. Q3 2025 Financial Summary
Altimmune, Inc. reported revenue of $5.0K for Q3 2025, with a net profit of $-19.0M (-380280.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $5.0K |
|---|---|
| Net Profit | $-19.0M |
| Gross Margin | N/A |
| Operating Margin | -417180.0% |
| Report Period | Q3 2025 |
Altimmune, Inc. Annual Revenue by Year
Altimmune, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $20.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $20.0K |
| 2023 | $426.0K |
| 2022 | $-68.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37000 | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 |
| YoY Growth | 133.6% | -76.2% | -16.7% | -98.6% | -86.5% | 0.0% | 0.0% | 0.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $210.6M | $188.4M | $173.3M | $147.9M | $139.3M | $157.3M | $190.3M | $218.4M |
| Liabilities | $16.5M | $15.4M | $20.8M | $14.5M | $15.8M | $15.1M | $29.0M | $32.8M |
| Equity | $194.1M | $172.9M | $152.5M | $133.4M | $123.5M | $142.2M | $161.4M | $185.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.5M | $-16.4M | $-18.1M | $-27.1M | $-18.3M | $-16.8M | $-19.4M | $-11.9M |